Canine Autoimmune Dermatoses: Current Evidence, Diagnostic Challenges and Therapeutic Perspectives

Canine autoimmune skin diseases (AISDs) comprise a complex spectrum of dermatoses resulting from the loss of immunological self-tolerance to epidermal, basement membrane zone or follicular self-antigens. This review critically synthesises current evidence on the immunopathogenesis, diagnostic challenges and evolving therapeutic paradigms of major canine AISDs. These disorders are broadly classified into antibody-mediated acantholytic conditions (the pemphigus complex), subepidermal blistering dermatoses (including bullous pemphigoid and epidermolysis bullosa acquisita) and lymphocyte-driven interface skin diseases (lupus erythematosus variants and canine uveodermatologic syndrome). Accurate diagnosis relies on integrating clinical lesion patterns with skin cytology, histopathology—which identifies key markers such as intraepidermal acantholysis, subepidermal clefting and interface dermatitis—and immunopathological verification using direct and indirect immunofluorescence. Systemic glucocorticoids combined with steroid-sparing immunosuppressants, such as azathioprine, ciclosporin and mycophenolate mofetil, remain the traditional mainstay during the induction, transition and maintenance phases. However, long-term toxicities, refractory cases and variable clinical responses highlight significant management challenges. Emerging targeted immunomodulatory agents—notably Janus kinase (JAK) inhibitors (oclacitinib) and Bruton’s tyrosine kinase (BTK) inhibitors—alongside advanced modalities such as intravenous immunoglobulin, therapeutic plasma exchange and mesenchymal stem-cell therapies, offer safer and more selective alternatives. Major research gaps persist, including reliance on small retrospective cohorts, the lack of standardised disease-activity scores and limited availability of specific immunoserological assays. Addressing these gaps requires prospective, multicentre controlled trials and biomarker-driven studies. Shifting the therapeutic landscape from broad-spectrum immunosuppression towards precision immunotherapy, cytokine-targeted biotherapeutics and antigen-specific tolerance will be vital to optimising long-term management and clinical outcomes in canine dermatology.

Authors

Institutions

Publication Details

Journal
Journal of Advances in Biology & Biotechnology
Published
2026-11-17
DOI
https://doi.org/10.9734/jabb/2026/v29i114696
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Canine Autoimmune Dermatoses: Current Evidence, Diagnostic Challenges and Therapeutic Perspectives

Abrar Ul Haq, Sushma Chhabra, Damini
Journal of Advances in Biology & Biotechnology
Autoimmune Bullous Skin Diseases
article

Canine Autoimmune Dermatoses: Current Evidence, Diagnostic Challenges and Therapeutic Perspectives

Abrar Ul Haq, Sushma Chhabra, Damini
article en

Abstract

Canine autoimmune skin diseases (AISDs) comprise a complex spectrum of dermatoses resulting from the loss of immunological self-tolerance to epidermal, basement membrane zone or follicular self-antigens. This review critically synthesises current evidence on the immunopathogenesis, diagnostic challenges and evolving therapeutic paradigms of major canine AISDs. These disorders are broadly classified into antibody-mediated acantholytic conditions (the pemphigus complex), subepidermal blistering dermatoses (including bullous pemphigoid and epidermolysis bullosa acquisita) and lymphocyte-driven interface skin diseases (lupus erythematosus variants and canine uveodermatologic syndrome). Accurate diagnosis relies on integrating clinical lesion patterns with skin cytology, histopathology—which identifies key markers such as intraepidermal acantholysis, subepidermal clefting and interface dermatitis—and immunopathological verification using direct and indirect immunofluorescence. Systemic glucocorticoids combined with steroid-sparing immunosuppressants, such as azathioprine, ciclosporin and mycophenolate mofetil, remain the traditional mainstay during the induction, transition and maintenance phases. However, long-term toxicities, refractory cases and variable clinical responses highlight significant management challenges. Emerging targeted immunomodulatory agents—notably Janus kinase (JAK) inhibitors (oclacitinib) and Bruton’s tyrosine kinase (BTK) inhibitors—alongside advanced modalities such as intravenous immunoglobulin, therapeutic plasma exchange and mesenchymal stem-cell therapies, offer safer and more selective alternatives. Major research gaps persist, including reliance on small retrospective cohorts, the lack of standardised disease-activity scores and limited availability of specific immunoserological assays. Addressing these gaps requires prospective, multicentre controlled trials and biomarker-driven studies. Shifting the therapeutic landscape from broad-spectrum immunosuppression towards precision immunotherapy, cytokine-targeted biotherapeutics and antigen-specific tolerance will be vital to optimising long-term management and clinical outcomes in canine dermatology.

Journal of Advances in Biology & BiotechnologyVol. 29(11)
Guru Angad Dev Veterinary and Animal Sciences University (IN)
Good health and well-being
Autoimmune Bullous Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon